Arsenic trioxide and olanzapine co-administration: case analysis.
QTc prolongation is associated with arsenic trioxide (ATO) treatment of acute promyelocytic leukemia (APL). Olanzapine was safely co-administered with ATO to treat co-morbid psychiatric diagnoses. It is important to closely monitor for drug-drug interactions and cumulative drug adverse effects in patients receiving oncology agents and psychotropics. Further research is indicated to determine risk/benefit profiles of psychotropics co-administered with ATO. In light of current limited data, co-administration of psychotropics with ATO should be reported presenting both instances wherein no interactions are noted and those with adverse effects.
Kaufman
Kenneth R
KR
Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. kaufmakr@umdnj.edu
Chhabra
Saurabh
S
Levitt
Michael
M
Sood
Rahul
R
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage* / Q000009:adverse effects; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004347:Drug Interactions; D016903:Drug Monitoring; D004562:Electrocardiography; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy*; D008133:Long QT Syndrome / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control; D008297:Male; D001523:Mental Disorders / Q000150:complications / Q000188:drug therapy*; D000077152:Olanzapine; D010087:Oxides / Q000008:administration & dosage* / Q000009:adverse effects; D061214:Patient Safety; D012307:Risk Factors
D000970:Antineoplastic Agents; D014150:Antipsychotic Agents; D001152:Arsenicals; D010087:Oxides; D001569:Benzodiazepines; D000077152:Olanzapine; D000077237:Arsenic Trioxide